Comparable investigation in dopamine transporters with 99mTc-TRODAT-1 and 131I-FP-CIT SPECT in Parkinson’s disease patients

被引：0

作者：

LIU Congjin1 LIU Xingdang1* ZHANG Guangming1 LI Ding1 WANG Jian2 YANG Liqin2 JIANG Yuping2 (1 Department of Nuclear Medicine

2 Department of Neurology

机构：

来源：

NuclearScienceandTechniques | 2007年 / 04期

关键词：

99mTc-TRODAT-1; SPECT; 131I-FP-CIT SPECT; Parkinson’s disease;

D O I：

暂无

中图分类号：

R742.5 [震颤麻痹综合征]; R817.4 [在诊断上的应用];

学科分类号：

1001 ; 100105 ; 1002 ; 100207 ; 100602 ;

摘要：

Dopamine transporter (DAT) mediates the regulation of dopaminergic function. Two agents of TRODAT-1 and FP-CIT were observed in evaluating DAT change of Parkinson’s disease (PD). The relationship between them was also evaluated. The results suggested that 99mTc-TRODAT-1 SPECT and 131I-FP-CIT SPECT may serve as sensitive and objective in vivo markers to reflect the severity of PD. The 99mTc-TRODAT-1 image is more accurate and clearer compared with 131I-FP-CIT.

引用

页码：232 / 236

页数：5

共 9 条

[1] LIU Xingdang,LIN Xiangtong,FANG Ping, et al. Chinese Journal of Nuclear Medicine . 2000
[2] LIU Xingdang,LIN Xiangtong. Chinese Journal of Nuclear Medicine . 2000
[3] LIU Xingdang,FANG Ping,CHEN Zhengping, et al. Chinese Journal of Nuclear Medicine . 2003
[4] Hughes A J,Daniel S E,Kilford L, et al. Journal of Neurology Neurosurgery and Psychiatry . 1992
[5] LIU Xingdang,GUO Liping,JIANG Chengchuan, et al. Shanghai Medical Journal . 2002
[6] LIU Xingdang,LIN Xiangtong. Chinese Journal of Nuclear Medicine . 2003
[7] LIU Xingdang,LIN Xiangtong,KUANG Qinfang, et al. Asian J Nucl Med . 2002
[8] Eshuis S A,Maquire R P,Leenders K L et al. European Journal of Nuclear Medicine and Molecular Imaging . 2006
[9] Booij J,Hemelaar J T G M,Speelman J D, et al. The Journal of Nuclear Medicine . 1999

← 1 →